scope and correctly believed that aesthetic concerns regarding the skin and its diseases should also be included to best serve students, practitioners, and, most importantly, patients. He also strengthened the DIGM "signature," the integration of the basic and clinical sciences, by soliciting from contributors new approaches to the biology, structure, and function of the skin. Further, he introduced or expanded sections on evidence-based dermatology, skin changes over the lifespan, dermatologic therapy, dermatologic surgery, and the emerging types of biologic therapy. At the same time, he reduced the roughly 3,000 pages of the unwieldy fourth and fifth editions to 2,600 pages in the most recent sixth edition, upgraded the illustrative material that now is in full color throughout the book, and had all diagrams redrawn for ease of interpretation. Under Irwin's leadership, all the chapters on basic science were extensively rewritten to reflect the enormous advances made during the preceding decade. DIGM being a classic, Irwin advocated renaming it Fitzpatrick's Dermatology in General Medicine to honor Dr Fitzpatrick, who had relinquished his role as a senior editor by the time of the fifth edition.
During production of the fifth and sixth editions, Irwin insisted on proofreading each chapter himself and reviewing the entire two-volume work to eliminate overlaps and redundancies. He was a relentless worker, and only his wife Irene knows how much time and effort he invested in this project. In recognition of his vision and ongoing contributions, after Irwin relinquished his membership of the DIGM editorial board, his co-editors (Lowell A. Goldsmith, Stephen I. Katz, Barbara A. Gilchrest, Amy S. Paller, David J. Leffell, and myself) asked him to remain as an advisor for the seventh edition, now in preparation, and he admirably fulfilled this responsibility until his untimely death.
Irwin was a strong-handed editor whose authority was based on personal integrity as well as on the breadth and depth of his knowledge. Irwin and I were fortunate to become physicians during the early years of the scientific revelations of the "new biology" that began to inform academic medicine. We both were medical house officers at Beth Israel Hospital in Boston during the latter days of Herman Blumgart's reign as chair of medicine. Superb clinical medicine prevailed with great emphasis on clinical-pathological correlation, infectious disease, and, most importantly, the observation, quantification, and manipulation of human physiology. These pursuits were the bedrock of academic medicine. But WatsonCrickery was in the air! At Beth Israel Hospital, Blumgart was succeeded by Howard Hiatt, recently returned from participating in the earliest days of the new biology at the Pasteur Institute. Hiatt brought a whole new vision of academic medicine. Irwin left Beth Israel Hospital during the Blumgart era to do his dermatology training at Massachusetts General Hospital and returned to join Hiatt in implementing a new paradigm of academic medicine. I too left for my training and a junior faculty position at Yale. After I returned to Boston, both Irwin and I were engaged in building our respective academic programs in the clinic and the laboratory. Not only was Irwin building dermatology; under Hiatt's leadership he, H. Richard Nesson, Howard Frazier, and others were remaking academic medicine at Beth Israel.
Irwin had spent the academic year 1961-1962 as a postdoctoral fellow in the biochemistry department at Brandeis University and that of 1969-1970 on a Guggenheim Fellowship at the Weizmann Institute in Israel. Both of these experiences equipped him with the tools of modern molecular science. The titles of two papers authored by Irwin and published by the New England Journal of Medicine capture these two phases of his academic medical research. The first, published in 1957, "The thyroid gland in pregnancy," was the kind of careful observation and quantification of human physiology that was characteristic of the academic medicine of the time. Irwin was the first author, and his coauthors were Milton Hamolsky (later to chair the Department of Medicine at Brown University) and Irwin's uncle A. Stone Freedberg, a distinguished cardiologist interested in the relationship between thyroid function and the heart. The second paper, "Rashes and ribosomes," authored only by Irwin and published just ten years later, offered promise of the practical relevance of basic molecular biology to clinical medicine. in combination with high energy and a passion for perfection, explain the level of excellence he achieved. All that he accomplished, he did for his profession and for us, his extended dermatologic family.
Irwin, we will miss you. We were bursting with energy and enthusiasm for our growing families, these medical and scientific enterprises, and life in general. Though this may not be imaginable today, federal funding for research was plentiful. Good and not so good ideas were funded, and, because funds were plentiful, offbeat but imaginative ideas could be pursued. Those were heady days! Commercial involvements were less common, health-care reimbursements were cost-based, and there was little competitive pressure among hospitals. In fact, inter-hospital collaboration was encouraged. Irwin developed a combined dermatology program for some of the Harvard-affiliated hospitals around the Harvard Medical School while I developed the Joint Center for Radiation Therapy for these and other hospitals. These programs were collaborative clinical, teaching, training, and research enterprises.
Easy funding, cost-based reimbursements, and, of course, our youth, along with a major saltation in science -the new biology -that resulted in a Kuhnian paradigm shift, made these the best of times. Others in this volume will discuss Irwin's academic contributions, but suffice it to say that he was very successful and drew notice. In 1977 Johns Hopkins convinced Irwin to resign his Harvard professorship in order to become the first chairman of their fledgling dermatology department. He leapt into this endeavor with his accustomed enthusiasm. Then, in 1981, the opportunities offered by chairmanship of the biggest, most distinguished and wellfinanced department of dermatology, as well as the allure of New York City, attracted Irwin to New York University to lead what is now the Ronald O. Perelman Department of Dermatology and to become the MacKee Professor. He reached the full flower of his academic potential during the almost quarter century of his tenure in that position.
Alas, during that time academic medicine changed and academic leaders faced new and different challenges. Research funding became more difficult, and funds from private and commercial sources became more important. As we both accepted senior positions in medicine in New York City -the heart of commercial and economic America -our dealings with the shakers and movers were extensive and necessary for the fulfillment of our missions. A small vignette to capture that time: I too was planning to leave a Harvard Medical School professorship for new opportunities in la Grande Pomme as the physician in chief at Memorial Sloan-Kettering Cancer Center. While considering and negotiating in New York, I stopped by to see Irwin and to ask about being a medical leader in that great city. He recollected that, in Boston, when we went to the symphony we saw many familiar faces, and being a professor in a medical school was a desired and respected position. This, he assured me, was also true in Baltimore. But things were different in New York. One rarely saw a familiar face at the opera or the symphony, and to those captains of industry, medical professors were not particularly important or respected. They were, however, collected and/or cultivated by these business leaders, primarily for possible medical advice and care for themselves and their families, colleagues, and employees. This was especially true for plastic surgeons.
Throughout the United States, medical-care concerns changed as well. Institutional competition, managed care, and containment of healthcare costs made academic medical practice much more difficult; all this occurred at the same time as much greater competition for a limited grant pool. Parenthetically, it should be noted that throughout the vicissitudes of funding availability, remarkably, Irwin's National Institutes of Health R01 grant "Epidermal Macromolecular Metabolism" received 40 years of continuous funding until 2001. Despite these challenges to medical leadership, both Irwin and his wife, Irene, flourished in New York professionally and personally. They partook of much that that city has to offer with their usual vigor and enthusiasm. Opera, symphony, theater, temple, friends, and, of course, family all vied for their time and attention. This would appear to be a full life, but it was not sufficient for Irwin, for he had a special feeling for New Hampshire. It was there, at Dartmouth, that he had received his undergraduate education, and Holderness is the site of the family retreat. His joie de vivre was fully requited by the lakes and mountains, in summer and winter, boating and swimming in the former and skiing in the latter, all in the company of his family and friends.
Irwin was committed to academic medicine throughout his final illness; he continued to work as long as possible and was busy reviewing book galleys almost to the end. He was very concerned about the state of academic medicine in general and dermatology in particular. He fretted about the increasing commercialism in both and the lure of procedural reimbursement affecting dermatology. At the same time, Irwin was excited about the great promise offered by the new biology to greatly improve medical care. These concerns generally applied to all of academic medicine.
When we began our medical careers we seemed to have boundless energy, invigorated as we were by the new biology and the opportunities it would offer to medicine. We had only limited concerns regarding health-care financing or the distribution of medical care. Collaboration rather than competition was the norm. In retrospect it seems that times were better then, but that is probably to be expected from those of us in our senior professional years when we look back at our youth. New opportunities, hazards, and diversions require agile reaction and real commitment. This is the only effective response to these interesting times. Irwin possessed these characteristics in abundance. From his great and enthusiastic capacity for work as a caring physician, scientist, and academic leader, to his joyous participation in skiing, swimming, boating, travel, and various cultural activities, Irwin was a man for all seasons, both figuratively and literally. He was also a mensch.
